 |
|
|
|
|
| |
|
- Valeant announces advancement of research and development funding to accelerate taribavirin Phase 3 clinical trials
- Valeant makes strategic acquisition of Amarin Pharmaceuticals, Inc., expanding the company's specialty neurology platform with Zelapar™
- Valeant presents 24-week data for Phase 2 of taribavirin at European Association for the Study of the Liver Conference in Berlin, Germany.
- Valeant forms Scientific Advisory Board of key opinion leaders to aid in strategic research and development planning
- Valeant acquires global rights to Tasmar®, further building the company's specialty neurology platform
- Valeant completes repurchase and redemption of 6 ½ percent convertible subordinated notes
- Valeant sells Czech Republic manufacturing operations
- Valeant initiates Phase 2 clinical trials for pradefovir for the treatment of hepatitis B
- Valeant completes enrollment in VISER1 - the first arm of Phase 3 trials for taribavirin.
- Valeant launches several line extensions for its dermatological product, Kinerase
- Valeant presents end-of-treatment data for taribavirin Phase 2 clinical trials at American Association for the Study of the Liver Conference
|
|
|
|
